Its mechanism of action is competitive binding with vascular endothelial growth factor (VEGF) receptor, inhibiting the migration and proliferation of endothelial cells, blocking angiogenesis and inhibiting tumor proliferation.8 At present, some reports show that bevacizumab combined with chemotherapy has certain benefits in the treatment of colon cancer.9,10 However, there is still a lack of high therapeutic research on the efficacy of bevacizumab combined with FOLFOX4 regimen in the treatment of advanced colon cancer. Here, VEGFA is linked to colonic neoplasm.